Susquehanna Fundamental Investments LLC Buys Shares of 51,703 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 51,703 shares of the medical device company's stock, valued at approximately $1,862,000. Susquehanna Fundamental Investments LLC owned about 0.08% of Tandem Diabetes Care at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. AlphaQuest LLC lifted its holdings in shares of Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after acquiring an additional 748 shares during the last quarter. McIlrath & Eck LLC bought a new position in shares of Tandem Diabetes Care during the third quarter valued at $52,000. Assetmark Inc. raised its position in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the stock in a transaction dated Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 1.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TNDM shares. Morgan Stanley downgraded Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective on the stock. Piper Sandler cut their target price on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Stifel Nicolaus reduced their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Barclays lowered their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of "Moderate Buy" and a consensus price target of $39.81.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded up $0.71 during midday trading on Tuesday, reaching $22.00. The company's stock had a trading volume of 289,383 shares, compared to its average volume of 1,492,708. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $1.47 billion, a PE ratio of -11.34 and a beta of 1.47. The stock has a fifty day moving average of $18.56 and a 200 day moving average of $28.43.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The business had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. Tandem Diabetes Care's revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.65) EPS. On average, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.